A patent foramen ovale (PFO) is a right‐to‐left intracardiac shunt pathway present in approximately 35% of the general healthy population. Individuals with a PFO (PFO+) exhibit higher alveolar to arterial oxygen difference (AaDO2) values at rest than subjects without a PFO (PFO−), indicating that PFO+ subjects have a source of right‐to‐left shunt significant enough to decrease gas exchange efficiency at rest. Additionally, PFO+ subjects have blunted ventilatory acclimatization to hypoxia compared to PFO− subjects. While the presence of a PFO is known to influence hypoxic chemosensitivity, it has yet to be determined if the presence of a PFO has an effect on the hypercapnic ventilatory response (HCVR).Thirty subjects (15 female) matched for height, weight, sex and age participated in this study. Subjects completed two hypercapnic breathing trials in a randomized and balanced order, separated by ≥ 40 minutes of rest between trials. At the start of each trial, subjects began breathing room air until steady‐state values for end‐tidal oxygen and carbon dioxide (PETO2 and PETCO2) were established. PETO2 and PETCO2 were then controlled utilizing a dynamic end‐tidal forcing system (AirForce). During the hyperoxic hypercapnia (HH) trial, PETO2 was clamped at 250 mmHg and PETCO2 was increased in a stepwise fashion to target values of +3 mmHg, +6 mmHg and +9 mmHg of each subject's baseline PETCO2. Each stage consisted of a 90 second steady‐state data collection period after each increase. The procedure for the normoxic hypercapnia (NH) trial was identical to the HH trial except that PETO2 was clamped at the resting baseline value for each subject and PETCO2 increased as above. Hypercapnic ventilatory response (HCVR) was calculated as the change in minute ventilation (VE) divided by the change in PETCO2 (L/min/Torr CO2).PFO+ subjects demonstrated a blunted, significantly lower HCVR than PFO− subjects during both the HH (PFO−: 1.80 L/min/Torr CO2 ± 0.17, PFO+: 1.19 L/min/Torr CO2 ± 0.14, p < 0.05) and NH (PFO−: 1.79 L/min/Torr CO2 ± 0.23, PFO+: 1.24 L/min/Torr CO2 ± 0.26, p < 0.05) trials. These data suggest that PFO+ subjects have a blunted ventilatory response to acute exposure to hypercapnia. Within the subset of female subjects, PFO+ females had a significantly lower HCVR than PFO− females in the HH trial (PFO−: 1.85 L/min/Torr CO2 ± 0.27, PFO+: 1.06 L/min/Torr CO2 ± 0.13, p < 0.05) and NH trial (PFO−: 1.81 L/min/Torr CO2 ± 0.28, PFO+: 1.15 L/min/Torr CO2 ± 0.11, p < 0.05). However, no differences were observed between the male PFO+ and PFO− subjects in the HH (PFO−: 1.77 L/min/Torr CO2 ± 0.37, PFO+: 1.35 L/min/Torr CO2 ± 0.24, p > 0.05) or NH (PFO−: 1.76 L/min/Torr CO2 ± 0.24, PFO+: 1.33 L/min/Torr CO2 ± 0.28, p > 0.05) trials. These results suggest that female PFO+ subjects have a blunted HCVR compared to female PFO− subjects.
Read full abstract